ATRX and non-small cell lung carcinoma: Consistent results were observed inclinical cohorts, in which overexpression of AHNAK was associated with poorprognosis of NSCLC (19).Overexpression of ATRX(19) and HNRNPA3(59) was observed in NSCLC tumors and poor prognosis patients.